Senate's Bipartisan Infrastructure Deal Aims To Let Researchers Study Marijuana From Dispensaries – Marijuana Moment

Four out of five Canadians support psilocybin-assisted therapy for people suffering from a terminal condition and say the government should set up a regulatory framework to allow such use, according to a new poll.

The Canadian Psychedelic Association (CPA) commissioned the survey, which the group says will bolster legislative proposals that it’s drafted for lawmakers.

Eighty-two percent of respondents said they back allowing the therapeutic use of psilocybin for people with terminal illnesses, and 78 percent would support the government establishing a legal regulatory model to facilitate that treatment.

Via CPA.

Another 64 percent said the psychedelic should be made available to qualifying patients under the Medical Assistance in Dying (MAID) rules.

CPA says the next step is to bring its Memorandum of Regulatory Approval (MORA) to Parliament. And previous discussions with legislators signal that there’s support for the effort to regulate psilocybin-assisted therapy for certain patients.

New polling data from Nanos Research says 8 in 10 Canadians support new #psilocybin regulations. We are preparing to introduce a collaborative effort to bring regulatory change to Health Canada. Read more about it here:

— Canadian Psychedelic Association (@cdnpsychedelic) August 4, 2021

“The MORA was prepared by some of the best researchers, industry, legal and regulatory experts in Canada,” Cory Firth, executive director of CPA, said in a press release. “As the voice of psychedelics in Canada, we made sure that no stone was left unturned in our efforts to bring timely and effective regulatory change to Canadians at end-of-life and suffering from various treatment-resistant mental health conditions.”

Pamela Kryskow, a doctor and psychedelics researcher, said the new poll results serve as “a green light for

Read More Here...

Share on facebook
Share on twitter
Share on reddit
Share on pinterest
Share on email

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top